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Abstract Activation of the Janus Kinase 2/Signal
Transducer and Activator of Transcription 3 (JAK2/
STAT3) pathway is known to play a key role in cardio-
genesis and to afford cardioprotection against ischemia–
reperfusion in adult. However, involvement of JAK2/
STAT3 pathway and its interaction with other signaling
pathways in developing heart transiently submitted to anoxia
remains to be explored. Hearts isolated from 4-day-old
chick embryos were submitted to anoxia (30 min) and
reoxygenation (80 min) with or without the antioxidant
MPG, the JAK2/STAT3 inhibitor AG490 or the Phos-
phoInositide-3-Kinase (PI3K)/Akt inhibitor LY-294002.
Time course of phosphorylation of STAT3atyrosine705 and
Reperfusion Injury Salvage Kinase (RISK) proteins [PI3K,
Akt, Glycogen Synthase Kinase 3beta (GSK3beta), Extra-
cellular signal-Regulated Kinase 2 (ERK2)] was deter-
mined in homogenate and in enriched nuclear and
cytoplasmic fractions of the ventricle. STAT3 DNA-binding
was determined. The chrono-, dromo- and inotropic dis-
turbances were also investigated by electrocardiogram and
mechanical recordings. Phosphorylation of STAT3atyr705
was increased by reoxygenation, reduced (*50%) by MPG
or AG490 but not affected by LY-294002. STAT3 and
GSK3beta were detected both in nuclear and cytoplasmic
fractions while PI3K, Akt and ERK2 were restricted
to cytoplasm. Reoxygenation led to nuclear accumulation
of STAT3 but unexpectedly without DNA-binding.
AG490 decreased the reoxygenation-induced phosphory-
lation of Akt and ERK2 and phosphorylation/inhibition of
GSK3beta in the nucleus, exclusively. Inhibition of JAK2/
STAT3 delayed recovery of atrial rate, worsened vari-
ability of cardiac cycle length and prolonged arrhythmias
as compared to control hearts. Thus, besides its nuclear
translocation without transcriptional activity, oxyradicals-
activated STAT3a can rapidly interact with RISK proteins
present in nucleus and cytoplasm, without dual interaction,
and reduce the anoxia–reoxygenation-induced arrhythmias
in the embryonic heart.
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Introduction
Although the embryo and the fetus develop normally in a
relatively hypoxic environment [7, 31], cardiovascular
function can be rapidly impaired by an accidental and
transient intrauterine lack of oxygen [21] with possible
long-term deleterious consequences. In the embryonic
heart, the chrono-, dromo- and inotropic disturbances
induced by anoxia–reoxygenation [39, 48] are associated
with overproduction of Reactive Oxygen Species (ROS)
and significant alterations of signaling pathways. In par-
ticular, the region-specific activation of Mitogen-Activated
Protein Kinases (MAPKs) [12, 43] such as p38MAPK,
extracellular signal-regulated kinase (ERK2) and c-jun
N-terminal kinase (JNK) and stimulation of protein kinase
C and nitric oxide synthases [44] are part of the mecha-
nisms involved in the response to anoxia–reoxygenation,
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with slight differences relative to the ischemic-reperfused
adult heart [18]. In addition to these signaling pathways,
the Janus Kinase 2/Signal Transducer and Activator of
Transcription 3 (JAK2/STAT3) pathway is also activated
by ischemia–reperfusion [1, 19]. JAK2 is a receptor-asso-
ciated cytosolic protein which mediates signals to the
nucleus by the subsequent phosphorylation/activation of
STAT3 transcription factor. STAT3 can be phosphorylated
on tyrosine705 by JAK upon activation and on serine727
mainly by ERK and p38MAPK [24]. It should also be
noticed that expression of STAT3 is necessary for normal
embryogenesis [53] and that JAK2/STAT3 activation is a
prerequisite for the differentiation of embryonic stem cells
into spontaneously beating cardiomyocytes [10]. More-
over, the JAK2/STAT3 pathway affords protection against
reperfusion-induced injury in neonatal [51] and adult [19,
37] cardiomyocytes and can interact with other pathways
including the Reperfusion Injury Salvage Kinase (RISK)
pathway [11, 13, 15, 17, 30]. The RISK pathway is a group
of pro-survival protein kinases including PhosphoInositide-
3-Kinase (PI3K), Akt/PKB, Glycogen Synthase Kinase
3beta (GSK3beta) and ERK1/2 which confers cardiopro-
tection when activated at reperfusion but not in all species
[50]. Although STAT3 is basically a transcription factor
shuttling between cytoplasmic and nuclear compartments,
the intracellular localization of its interactions with RISK
pathway components as well as its role in cardiac function
under pathological conditions remains to be explored. This
work aimed (1) to establish the temporal profile of phos-
phorylation, the mechanisms of activation and the tran-
scriptional activity of STAT3, (2) to assess the crosstalk
between STAT3 and RISK pathway in the nuclear and the
cytoplasmic compartments, and (3) to examine the role of
activated STAT3 in the functional recovery of the anoxic-
reoxygenated embryonic heart.
Materials and methods
Reagents
Dimethylsulfoxide (DMSO) and antioxidant N2-mercap-
topropionylglycine (MPG) were purchased from Sigma–
Aldrich, JAK2/STAT3 inhibitor AG490 and PI3K/Akt
inhibitor LY-294002 from Calbiochem and proteases
inhibitors from Roche Biosciences. Rabbit antibody against
phospho-Tyr705-STAT3 was from Ab Frontier. Antibodies
against phospho-Ser727-STAT3, phospho-Tyr458-PI3K,
PI3K, phospho-Ser473-Akt, Akt, phospho-Ser9-GSK3beta,
GSK3beta, phospho-Ser641-GS, GS, phosphorylated ERK
and ERK were from Cell Signaling Technology. Antibody
against STAT3 was from Santa Cruz Biotechnology and
the secondary antibody (goat anti-rabbit HRP conjugated)
was from GE Healthcare. The enhanced chemilumines-
cence (ECL) western blot reagent kit was from PerkinElmer
and films from GE Healthcare.
Preparation and in vitro mounting of the heart
Fertilized eggs from Lohman Brown hens were incubated
during 96 h at 38C and 90% relative humidity to obtain
stage 24HH embryo (according to Hamburger and Hamil-
ton [16]). The spontaneously beating hearts were carefully
excised from explanted embryos by section at the level of
the truncus arteriosus as well as between the sinus venosus
and the atria. As previously described [45], the hearts were
then placed in the culture compartment of a stainless steel
chamber equipped with two windows for observation and
maintained under controlled conditions on the thermosta-
bilized stage (37.5C) of an inverted microscope (IMT2
Olympus, Tokyo, Japan). Briefly, the incubation compart-
ment (300 lL) was separated from the gas compartment by
a 15 lm transparent and gas-permeable silicone membrane
(RTV 141, Rhoˆne-Poulenc, Lyon, France). Thus, PO2 at
the tissue level was strictly controlled and rapidly modified
(within less than 5 s) by flushing high-grade gas of selected
composition through the gas compartment. The standard
HCO3/CO2 buffered tyrode (supp. file) medium was
equilibrated in the chamber with 2.31% CO2 in air con-
taining 19.5% O2 (normoxia and reoxygenation) or in N2
(anoxia) yielding a pH of 7.4. AG490 was reconstituted in
DMSO. MPG, AG490 and LY-294002 were diluted in
tyrode containing 0.5, 0.006 and 0.006% DMSO (vehicle),
respectively, and present throughout the experimental
protocol.
Anoxia–reoxygenation protocol
After a 30 min pretreatment at room temperature in vehi-
cle, MPG (1 mM), AG490 (10 lM) or LY-294002
(10 lM), hearts were mounted in the chamber, stabilized
45 min under normoxia and submitted to anoxia (30 min)
and reoxygenation (80 min). The hearts were harvested
after stabilization (S), 10 (A10) and 30 min (A30) of
anoxia and 10 (R10), 30 (R30), 40 (R40), 50 (R50), 60
(R60) and 80 min (R80) of reoxygenation. Control hearts
were maintained under steady normoxia 60 and 90 min
after S, corresponding to the time points R30 and R60,
respectively. At the end of the experiment, the ventricles
were carefully dissected on ice and stored at -80C for
subsequent determinations.
Protein homogenate
For each sample, three ventricles were pooled because of
the very small size of hearts. Ventricles were homogenized
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by sonication 3 9 2 s in the ice-cold lysis buffer (supp.
file) and protein content was measured by the method of
Bradford (Coomassie protein assay kit, Pierce) with bovine
serum albumin as standard.
Immunoblotting
Proteins from cellular extracts (20 lg) were boiled with 1/3
of SDS sample buffer (supp. file), separated on 10% SDS-
polyacrylamide gels (1 h, 185 V), and transferred to
nitrocellulose membranes (2 h, 100 V). The equal loading
in the membranes was systematically verified by per-
forming Red Ponceau and by determining densitometry of
total proteins and GAPDH. Membranes were probed with
primary antibodies against phospho-Tyr705-STAT3 and
phospho-GS (1:750); phospho-Ser727-STAT3, phospho-
PI3K, STAT3 and PI3K (1:500); phospho-Akt, phospho-
GSK3beta, phospho-ERK, Akt, GSK3beta, GS and ERK
(1:1,000) diluted in 5% bovine serum albumin in tris-buf-
fered saline tween (TBS-T, supp. file) (overnight, 4C).
Blots were then incubated (1 h, room temperature) with the
secondary antibody (1:10,000) in 1% non-fat milk in TBS-
T. Immunoreactive bands were detected using the ECL
western blot reagent kit. Signal was semi-quantitatively
analyzed using scanning densitometry (Quantity One
software, Biorad). Bands of phosphorylated proteins were
normalized to the total protein in the same sample and in
the same membrane. More specifically for STAT3, the
phospho-a isoform (P-STAT3a) was normalized to the
total a isoform. Phosphorylation level at each time point of
anoxia and reoxygenation was normalized to the respective
preanoxic S level. We used total cell extracts from serum-
starved HeLa cells prepared with IFN-a treatment (Cell
Signaling Technology) as a positive control for P-Tyr
STAT3, in which the a isoform was largely predominant
relative to the beta isoform.
Enriched nuclear and cytoplasmic fractions preparation
Cytoplasmic and nuclear extracts were obtained as descri-
bed elsewhere [27]. Twelve ventricles were homogenized in
hypotonic buffer (supp. file). After addition of detergent
Nonidet P-40 (0,625%) and centrifugation, supernatants
containing the cytoplasmic proteins were stored at -80C.
Pellets were resuspended in hypertonic buffer (supp. file),
centrifugated and the resulting supernatants (nuclear frac-
tions) were collected and stored at -80C. Protein content
was measured by the method of Bradford.
Electrophoretic mobility shift assay
A STAT3 oligonucleotide probe (supp. file) was labeled
with a-32PdCTP using the Klenow enzyme (Roche Applied
Science). 10 lg of nuclear proteins were incubated with
EMSA buffer (supp. file) and the probe for 20 min at room
temperature. Samples were resolved on a nondenaturing
polyacrylamide gel. Gels were transferred to Whatman
3 M paper, dried under vacuum, and exposed to photo-
graphic films at -80C with intensifying screens. Densi-
tometric analysis of autoradiographs was performed. A
negative control was performed using either an antibody
against STAT3 or an unlabeled probe. Ventricles isolated
from hearts treated with H2O2 at 1 mM for 1 h were used
as a positive control for STAT3.
Quantitative RT-PCR
Twelve ventricles were homogenized in trizol (Invitrogen)
and total RNA were purified by slight modifications of the
method originally described by Chomczynski & Sacchi [8].
The reverse transcription (RT) reaction was performed
using the High capacity cDNA Reverse Transcription Kit
and protocols from Applied Biosystem (ABI, Foster City,
CA, USA). Briefly, the RT was run with 1.5 lg of total
RNA in a reaction volume of 20 ll and aliquots of this
reaction mixture (supp. file) were used for the subsequent
PCR reactions. 5 ng of cDNA was laid per well. Results
are calculated using the DCt method [29].
Recording of electrical and contractile activities
Electrical and contractile activities were recorded simul-
taneously and continuously throughout in vitro experiments
as previously described [45]. The PR and RR intervals, the
QT duration, the ventricular apical shortening and the
electromechanical delay (EMDv) were determined as pre-
viously described [45]. The maximal velocity of contrac-
tion and relaxation was calculated from the maximal
positive and negative values of the first derivative of
shortening and relaxation, respectively. Atrial rate was
determined by measuring the delay between two P waves
and the RR interval by the delay between peaks of two
successive QRS complexes. We also assessed QRS wide-
ning, reflecting a possible reduction of ventricular con-
duction, by measuring the half-width of the QRS complex.
Statistical analysis
Because of the very small size of the heart (circa 60 lg pro-
teins) a total of about 2,300 chick embryos have been used in
this study. Results are given as mean ± standard error of the
mean (SEM) for immunoblotting densitometry and as
mean ± standard deviation (SD) for functional parameters.
The significance of any difference between two time points or
two conditions was assessed using Mann–Whitney test. The
statistical significance was defined by a value of p B 0.05.
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Results
Profile of STAT3 phosphorylation and STAT3 nuclear
translocation during anoxia–reoxygenation
Only the a isoform of P-Tyr STAT3 was detectable under
our conditions although both a (*92 kDa) and beta
(*83 kDa) STAT3 isoforms were expressed in the ven-
tricle (Fig. 1a). P-Tyr STAT3a was not affected by anoxia
(A10, A30) but increased during the first 60 min of
reoxygenation (from R10 to R60) and returned to basal
level at R80 (Fig. 1b). It should be noted that P-Tyr
STAT3a increase was more pronounced at R10 and R60.
By contrast, P-Ser STAT3a was not altered throughout
reoxygenation compared to preanoxic level (Fig. 1b), the
beta isoform bearing no serine phosphorylation site. The
time-matched normoxic controls at S, R30 and R60 did not
exhibit change in P-Tyr STAT3a indicating that the culture
conditions did not alter STAT3 activation relative to pre-
anoxia (Fig. 1b). In the nuclear fraction P-Tyr STAT3a
increased at R10 and tend to increase at R60 (p = 0.095)
(Fig. 1c) whereas STAT3 was significantly increased
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Fig. 1 Profile of STAT3a
activation in homogenates,
nuclear and cytoplasmic
fractions of the ventricle during
anoxia–reoxygenation.
a Representative immunoblots
of the a isoform of tyrosine
phosphorylated STAT3 (P-Tyr
STAT3a), serine
phosphorylated STAT3 (P-Ser
STAT3a) and a and beta
isoforms of STAT3 during
anoxia (A10 and A30) and
reoxygenation (R10 to R80) in
homogenates. b Densitometric
analysis of P-STAT3a
normalized to STAT3a. Black
columns represent P-Tyr
STAT3a and hatched columns
P-Ser STAT3a during anoxia–
reoxygenation and open
columns P-Tyr STAT3a in
normoxic controls at matching
time-points S, R30 and R60.
Representative immunoblots at
S, R10, R60 and R80 and
densitometric analysis of P-Tyr
STAT3a (c) and STAT3a and
STAT3beta (d) in enriched
nuclear fraction; P-Tyr STAT3a
(e) and STAT3a and
STAT3beta (f) in cytoplasmic
fraction. Data are expressed as
fold change relative to the
preanoxic value (S). *p \ 0.05,
**p \ 0.01, ***p \ 0.001
versus S. N = 4–9
determinations for b and
N = 4–13 determinations
for c–f
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throughout reoxygenation (Fig. 1d). By contrast, in the
cytoplasmic fraction P-Tyr STAT3a and STAT3 were not
affected (Fig. 1e, f). As total STAT3 increased in the
nuclear fraction (Fig. 1d), P-Tyr STAT3a obtained in both
fractions was not corrected for total STAT3 in Fig. 1c, e.
Involvement of STAT3 in functional recovery
of the anoxic-reoxygenated embryonic heart
The recovery of atrial rate during reoxygenation was
impaired and the coefficient of variability of the mean
atrial rate was worsened by JAK2/STAT3 inhibition
(Fig. 2a; Table 1). It should be noticed that during the first
15 min of reoxygenation the coefficient of variability of the
mean atrial rate was increased in untreated hearts as well
because of the unavoidable interferences of the reoxygen-
ation-induced arrhythmias as described elsewhere [45].
However, at R30 the beat-to-beat variability of RR was
clearly higher in AG490-treated hearts (Fig. 2b, c). All the
other electrical and mechanical parameters were not sig-
nificantly affected by AG490 (Table 1), i.e. atrioventricular
(PR interval) and intraventricular conduction (QRS wid-
ening), QT duration and excitation–contraction coupling
(EMDv). AG490 had no inotropic (shortening) or lusitropic
(relaxation) effects. The types of arrhythmias (including
atrial ectopy, atrioventricular block, Wenchebach) were
similar in treated and untreated hearts. Furthermore,
arrhythmias persisted throughout reoxygenation in 30% of
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Fig. 2 STAT3 inhibition
affected recovery of atrial
rhythm during reoxygenation.
a Mean atrial rate during
anoxia–reoxygenation relative
to the preanoxic level in vehicle
(open triangles, n = 5) or in
10 lM AG490 (black diamonds,
n = 9), mean ± SD. Note the
greatest SD in treated hearts
throughout reoxygenation.
*p \ 0.05 versus vehicle.
b Representative ECGs with P,
R and T components in vehicle
(V2, upper left panel) or in
AG490 illustrating arrhythmias,
i.e. PR prolongation followed
by atrioventricular block (AVB;
AG2, lower left panel) and
variations of RR interval from
one cardiac cycle to another at
R30 (AG5, right panel).
c Distribution of individual RR
intervals in five untreated hearts
(vehicle, V1–V5) and in nine
AG490-treated hearts (AG1–
AG9) at R30. The beat-to-beat
analysis was performed on 100
successive cycles
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the treated hearts, while they ceased at R30 in all other
hearts.
ROS-dependent STAT3a activation during post-anoxic
reoxygenation
The level of P-Tyr STAT3a was significantly decreased
by MPG at R10 and R60, time-points at which activation
of STAT3 was the strongest, with no effect at S (Fig. 3).
The level of P-Tyr STAT3a at R10 in Fig. 3 was lower
than that shown in Fig. 1a, this effect was due to vari-
ability between experiments and/or the conditions of
immunoblotting.
STAT3 DNA-binding
STAT3 DNA-binding activity determined by EMSA
(Fig. 4a) did not vary during reoxygenation as illustrated
by densitometry (Fig. 4b). Ventricles from hearts treated
with H2O2 were used as a positive control to show that the
technique was sensitive enough to detect any change in
STAT3 DNA-binding activity in this embryonic tissue
(?33% in hearts treated with H2O2) (Fig. 4c). A negative
control of DNA-binding performed by adding an antibody
against STAT3 or an unlabeled probe to the samples
showed that the upper band corresponding to STAT3
disappeared under these two conditions (Fig. 4c). The
unexpected finding that STAT3 was translocated without
DNA-binding was supported by the fact that the level of
mRNA expression of three STAT3 specific target genes in
the context of ischemia–reperfusion, i.e. inducible NO
synthase (iNOS), manganese superoxide dismutase (MnSOD)
and cyclooxygenase-2 (Cox-2), was not increased even at R80
(data not shown).
Table 1 Functional parameters under normoxia and during
reoxygenation
S R10 R30 R60
Mean atrial rate (bpm)
v 191 ± 8 202 ± 31 198 ± 8 185 ± 8
AG 160 ± 26 193 ± 27 180 ± 33 170 ± 28
Coefficient of variability of the mean atrial rate (%)
v 4 15 4 4
AG 16 14 18 17
PR interval (ms)
v 133 ± 22 169 ± 34 143 ± 35 126 ± 32
AG 128 ± 33 145 ± 25 126 ± 29 119 ± 33
QT duration (ms)
v 153 ± 10 182 ± 5 153 ± 19 150 ± 26
AG 149 ± 12 137 ± 9 131 ± 9 139 ± 11
Contraction/relaxation velocity ratio
v 0.96 ± 0.26 0.93 ± 0.28 1.00 ± 0.14 1.00 ± 0.21
AG 1.05 ± 0.12 0.91 ± 0.28 1.03 ± 0.30 1.20 ± 0.18
Ventricular shortening (lm)
v 16.5 ± 9.6 7.8 ± 8.7 18 ± 15 10.7 ± 8.5
AG 14.1 ± 7.9 9.0 ± 6.2 9 ± 8 26 ± 26
EMDv (ms)
v 26 ± 10 54 ± 4 33 ± 1 26 ± 9
AG 25 ± 4 28 ± 10 25 ± 3 27 ± 5
QRS half-width (ms)
v 3.4 ± 1.5 3.7 ± 2.0 3.2 ± 0.8 4.6 ± 2.0
AG 3.0 ± 1.3 4.26 ± 2.0 3.5 ± 1.6 3.2 ± 1.5
Electrical and mechanical parameters were not different in vehicle
(V) and in 10 lM AG490 (AG) at S, R10, R30 and R60. However, the
interindividual coefficient of variability of the mean atrial rate
appeared to be the highest in AG490-treated group at S, R30 and R60.
Mean ± SD; Mann–Whitney test, N = 3–9 determinations
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Distribution of PI3K, Akt, GSK3beta, glycogen
synthase (GS) and ERK2 and possible crosstalk
with STAT3
Using histone H1 and GAPDH as specific markers of
enriched nuclear and cytoplasmic fractions, respectively,
we found that phosphorylated and total forms of PI3K, Akt,
GS and ERK2 were restricted to cytoplasm. Basal level of
phosphorylated GSK3beta was markedly higher in the
nuclear fraction than in the cytoplasmic fraction whereas
the total form of GSK3beta was comparable in the two
compartments (Fig. 5). The temporal pattern of phosphory-
lation varied from one component of the RISK pathway to
another. PI3K and Akt phosphorylation peaked at R10
(Fig. 6a, b) while GSK3beta as well as GS phosphorylation
was increased at R10 and R60 (Fig. 6c, d). Relative to the
latest proteins, ERK2 phosphorylation was delayed at R60
(Fig. 6e). The possibility of interaction between RISK and
JAK2/STAT3 pathways was assessed pharmacologically
by AG490, a common JAK2/STAT3 pathway inhibitor. As
expected, AG490 significantly decreased P-Tyr STAT3a
and P-Akt at R10 and R60 as well (Fig. 7a, c). AG490
reduced GS (Fig. 7d) and ERK2 (Fig. 7e) phosphorylation
at R10 only with no effect on PI3K phosphorylation
(Fig. 7b). GSK3beta being the only protein of the RISK
pathway present in the nuclear compartment, together with
STAT3, we checked separately the effect of STAT3 inhi-
bition on the phosphorylation level of nuclear GSK3beta
(Fig. 8). Nuclear and cytoplasmic P-GSK3beta signifi-
cantly increased between S and R10 while GSK3beta did
not vary (Fig. 8a). GSK3beta phosphorylation was
decreased by AG490 in the nuclear fraction at R10
(Fig. 8b) but remained unchanged in the cytoplasmic
fraction (Fig. 8c). The possible effect of PI3K/Akt on
STAT3 phosphorylation was evaluated pharmacologically
using LY-294002, a common PI3K/Akt pathway inhibitor.
As expected, LY-294002 decreased P-Akt by 55% at R10
(Fig. 9a) but did not affect P-Tyr STAT3a (Fig. 9b).
Discussion
To the best of our knowledge, this is the first time that the
modulation of the JAK2/STAT3 pathway by a transient
anoxic stress and its functional consequences are explored
during early cardiogenesis. Our main findings indicate that
(1) reoxygenation induces ROS-dependent phosphorylation
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of Tyr-STAT3a but not Ser-STAT3a, (2) P-Tyr STAT3a
translocates into the nuclear compartment without binding
to DNA and inhibits GSK3beta, (3) phosphorylation of
STAT3a activates Akt and ERK2 and inhibits GS in the
cytoplasmic compartment, (4) there is no dual interaction
of STAT3 with proteins of the RISK pathway, and (5)
activation of the JAK2/STAT3 pathway reduces the
reoxygenation-induced arrhythmias.
Characteristics and limitations of the model
In the embryonic ventricle, only STAT3 and GSK3beta
appeared to be present both in the nuclear and cytoplasmic
fractions. PI3K, Akt, GS and ERK2 were restricted to the
cytoplasm, whereas in neonatal and adult cardiomyocytes
PI3K [42], Akt [35] and ERK [38] are detected also in the
nuclear compartment. These observations suggest that the
cytoplasm–nucleus shuttling of proteins, including tran-
scription factors, may well depend on the level of differ-
entiation and maturation of the cardiomyocytes. We were
able to detect JAK2 by immunoblotting (not shown) but it
was technically difficult to reveal its phosphorylated form
with antibodies available on the market. AG490, a tyrosine
kinase inhibitor which reduces JAK2 activity, significantly
decreased the reoxygenation-induced STAT3 phosphory-
lation as expected, which validates this pharmacological
approach to rapidly interfere with the JAK2/STAT3 path-
way. Regarding ERK, as previously shown [12], only the
p42 isoform (ERK2) is detectable in the embryonic and
adult chicken heart, in contrast to neonatal and adult
murine heart. As mentioned elsewhere [44], the isolated
embryonic heart displays noticeable interindividual
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variations of the functional parameters and ECGs per-
formed in similar conditions can also modestly differ in
morphology from one experiment to another. Such varia-
tions could be due to slight interindividual differences in
developmental stage, three-dimensional geometry of the
hearts mounted in the chamber and variable vicinity of the
recording electrodes. It is also conceivable that intrinsic
oscillations of activation of signaling pathways in the
embryonic cardiomyocytes [23], combined with variable
rate of proliferation and differentiation in the different cell
populations, could partly contribute to increase the inter-
individual variations of STAT3 phosphorylation deter-
mined at a given time point (specially at R60). A
significant variability of the phosphorylation level of sig-
naling proteins such as JNK, p38 and ERK2, has also been
observed in the same experimental setting [12, 43]. It
should be noticed that, contrary to the adult, the ventricle
of the 4-day old embryonic chick heart is mostly composed
of proliferating and differentiating cardiomyocytes with
few endothelial and epicardial cells and no fibroblasts [49].
STAT3 phosphorylation and translocation
during anoxia–reoxygenation
The full-length STAT, the a isoform, can undergo alter-
native splicing at the 30 end gene transcripts leading to
shorter beta isoform with truncated C-terminal domain
(lacking 48 amino acids) [28]. STAT3a and STAT3beta are
distinctly different in their activation, transcriptional
activities, and biological functions [47]. Our data indicate
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that a and beta isoforms of STAT3 are strongly expressed
in the embryonic heart but that only the a isoform is
responsive to post-anoxic reoxygenation whereas
STAT3beta is known to have a critical developmental
function [9] which was not investigated in this work. As
tyrosine rather than serine site was phosphorylated by
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reoxygenation, the possibility of STAT3 activation by
MAPKs [24] can be ruled out under our conditions since
serine is preferentially phosphorylated by these pathways.
More specifically, although p38MAPK and ERK2 are
known to be activated at R10 and R30, respectively [12],
they did not phosphorylate STAT3Ser727. At R10 activation
of STAT3 observed in homogenate principally reflected
what took place in the nuclear compartment since only
nuclear P-Tyr STAT3a increased significantly as in phar-
macological postconditioned adult murine hearts [26]. At
R60 nuclear P-Tyr STAT3a tended to remain higher than
the preanoxic level and the rise in nuclear STAT3 observed
at R10 persisted throughout reoxygenation suggesting that
translocated STAT3 was sequestered in the nuclear com-
partment. An increase in nuclear phosphorylated STAT3 is
observed also in the ethanolamine-induced protection of
the adult heart against ischemia–reperfusion injury [22].
The presence of mitochondrial STAT3 in our prepara-
tion cannot be ruled out since STAT3 is known to be
present in mitochondria of several tissues [2, 14, 55] and it
has also recently been shown that mitochondrial activated
STAT3 contributes to cardioprotection by stimulation of
respiration and inhibition of mPTP opening [4]. However,
in embryonic myocardium mitochondria are scarce and not
fully differentiated by contrast with adult tissue and their
contribution to the cellular content of STAT3, if any,
should be minor.
Involvement of the JAK2/STAT3 pathway
in cardiac rhythm
We have previously shown that the embryonic heart fully
recovers at R60 [44] but the signaling pathways underlying
the mechanisms of recovery remain relatively unexplored.
Activated STAT3 is known to exert its late cardioprotec-
tive action (e.g., antiapoptotic properties [30]) mainly via
alteration of transcription of target genes principally
induced by pre- or postconditioning [3]. However, the
short-term consequences of STAT3 activation on the
electrical and mechanical activities have never been
investigated, including those in the developing heart. At
R30, inhibition of JAK2/STAT3 gave rise to the highest
variability of atrial rate and RR interval, indicating that
activation of STAT3 is involved in recovery of atrial and
ventricular rhythm. As there are no extrinsic innervation at
the embryonic stage investigated and no neurohumoral
influence in the culture chamber, the fluctuations of rhythm
(dysrhythmias) originated exclusively at the level of the
pacemaker tissues, independently of the physiological
spontaneous oscillations of heart rate reported previously
[45]. These observations and the fact that arrhythmias
persisted throughout reoxygenation in 30% of the AG-
treated hearts, strongly suggest that activated STAT3 can
protect cardiac automaticity by interacting with pacemak-
ing mechanisms, especially under pathological conditions.
We have previously shown that subtle modulation of
L-type calcium, KATP and HCN channels can improve
postanoxic recovery of the embryonic heart [6, 44, 46, 54].
It is conceivable that crosstalk between JAK2/STAT3 and
RISK pathways may directly or indirectly control finely
these ion channels affecting membrane potential, and
contributing to protect pacemaker rate under adverse con-
ditions. However, our present findings show clearly that
activated STAT3 has no dromo-, ino- and lusitropic effects
in the anoxic-reoxygenated embryonic heart since atrio-
ventricular (PR) and intraventricular (QRS widening)
conduction, ventricular contractility (shortening) and
relaxation (ratio contraction/relaxation velocity) as well as
excitation–contraction coupling (EMDv) were not affected
by STAT3 inhibition. Additionally, the types of arrhyth-
mias during anoxia and reoxygenation we previously
documented [45] were similar in untreated and AG-treated
hearts.
ROS-dependent STAT3a activation during post-anoxic
reoxygenation
Our present finding that STAT3a phosphorylation on
tyrosine was ROS-dependent at R10 and R60 is consistent
with our preliminary data showing that exogenous H2O2
also activates STAT3 [Pedretti et al. (personal communi-
cation)] and with studies performed in neonatal cardio-
myocytes [30] and adult myocardium [33]. However, at
R10 there is a strong burst of ROS whereas at R60 ROS
production returns to its preanoxic level [44] suggesting
that the ROS-dependent mechanisms of STAT3 activation
are different during the early (R10) and late (R60) phases
of reoxygenation. This phenomenon could be partly due to
chemical differences between radical species produced at
R10 and R60 (i.e. superoxide anion O2
•- being predomi-
nantly generated during early reoxygenation) and to vari-
ations of the relative contribution of mitochondrial and
extramitochondrial (mainly NADPH oxidases) sources of
oxyradicals throughout reoxygenation [40]. This issue
deserves further investigation. The concept of the ROS-
mediated protection is also verified in permeabilized car-
diac muscle fibers in which the mitochondrial tolerance to
anoxia–reoxygenation is improved by TNFa through ROS
production [25].
STAT3 DNA-binding during anoxia–reoxygenation
After its activation STAT3 is known to dimerize and
subsequently translocate into the nuclear compartment,
where it can modulate expression of specific target genes
[20] including iNOS, MnSOD and Cox-2 known to be
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involved in cardioprotection [5, 36, 44]. The facts that
STAT3 DNA-binding activity was not altered and that
mRNA level of these genes remained stable throughout
reoxygenation indicate that translocated STAT3 had no
detectable transcriptional activity. Additionally, the level
of STAT3 phosphorylation on serine remained constant
throughout the experimental protocol (*2 h), STAT3
requiring phosphorylation on both sites (tyrosine and ser-
ine) to be maximally active in the assembly of active
transcription complexes [56]. As activated STAT3 was not
linked to DNA, we investigated the possible interaction
with other signaling pathways, in particular with the RISK
pathway.
Crosstalk between JAK2/STAT3 and RISK pathways
It is still unknown to what extent the survival kinases of the
RISK pathway are activated by anoxia–reoxygenation as
opposed to ischemia–reperfusion. The temporal profile of
phosphorylation shows that components of the RISK
pathway (ERK and PI3K-Akt-GSK3beta cascade) were
differently modulated during the early (R10) and late (R60)
phases of reoxygenation. Phosphorylation of PI3K, Akt and
GSK3beta was maximal at R10 whereas activation of
ERK2 was delayed at R60 as previously described [12].
The AG490-mediated reduction of phosphorylation of Akt,
ERK2 and nuclear GSK3beta indicates clearly that acti-
vation of the JAK2/STAT3 pathway can modulate RISK
components upon reoxygenation (R10) both in the cyto-
plasmic (Akt and ERK2) and nuclear (GSK3beta) com-
partments. We checked the presence of ERK2 in the
nuclear compartment in basal conditions whereas ERK2
translocates into the nucleus only when it is phosphory-
lated. At R10 we found an interaction between ERK2 and
STAT3 in homogenate but did not assess specifically the
effect of AG490 on ERK2 phosphorylation in nucleus and
cytoplasm because ERK2 was not phosphorylated at R10
and consequently not present in the nucleus. The strong
basal phosphorylation/inhibition of GSK3beta in the
nuclear compartment might be a characteristic of the rap-
idly growing embryonic ventricle. The additional inhibi-
tory effect of STAT3 on nuclear GSK3beta in the first
10 min of reoxygenation may be determinant as GSK3beta
is known to regulate many transcription factors and mod-
ulate cellular functions [34]. In H2O2-treated neonatal [30]
and ischemic-reperfused adult [11, 13, 15] cardiomyocytes
STAT3 inhibition reduces also Akt and GSK3beta phos-
phorylation but the intracellular localization has not yet
been established. However, our results show that a pref-
erential and predominant interaction between JAK2/
STAT3 pathway and Akt persists throughout reoxygena-
tion since AG490 leads to strong inactivation of Akt up to
R60, which is not the case for GSK3beta, ERK2 and GS.
Whatever the time point investigated, reoxygenation-
induced activation of PI3K was unrelated with JAK2/
STAT3 pathway in the embryonic heart like an ischemic-
reperfused heart model [13], although such a dissociation
remains controversial [52]. Furthermore, GS which is a
downstream target of GSK3beta, was strongly phosphory-
lated/inhibited from R10 onward, despite the fact that the
phosphorylated form of GSK3beta was inactive. Conse-
quently, other kinases such as PKA, AMPK, CK1 or CK2
[32] may phosphorylate/inhibit GS, reducing glycogen
storage which is known to be specially important in the
embryonic myocardium and to play a cardioprotective role
[41]. The mechanisms by which activation of JAK2/
STAT3 pathway phosphorylate GS at R10 and might
transiently reduce glycogen synthesis are beyond the scope
of this work. At R10, it appears that there is no dual
interaction between PI3K/Akt and JAK2/STAT3 pathways
in the embryonic heart. Such an interaction remains con-
troversial in neonatal and adult cardiomyocytes and
depends on the type of pathological situation such as
ischemic [52] and pharmacological pre- [15, 52] and
postconditioning [13] and oxidant stress [30]. Regarding
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the importance and the relevance of the RISK pathway, it
should be noticed that Skyschally et al. [50] showed that, in
hearts of larger mammals like pigs, RISK activation might
not be necessary for postconditioning.
In conclusion, this study shows for the first time that
the JAK2/STAT3 pathway plays a complex role in the
myocardial response to anoxia–reoxygenation during a
critical period of cardiogenesis. Indeed, besides its nuclear
translocation, the reoxygenation-activated transcription
factor STAT3 is also capable of interacting rapidly with
various signaling proteins of the RISK pathway present in
distinct cellular compartments (Fig. 10). Furthermore, the
fact that STAT3 activation improved post-anoxic recovery
of cardiac rhythm illustrates the potential role that STAT3
could play in the protection of cardiovascular function in
a developing organism. Our findings might be of rele-
vance to better understand the adaptative response of
the heart to intermittent, transient or chronic oxygen
deprivation during early fetal life, a relatively unexplored
area.
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